PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New PneumaCult™-ALI Medium for Air-Liquid Interface Culture of Bronchial Epithelial Cells - A new culture medium for more physiologically relevant differentiation of human bronchial epithelial cells has been released by STEMCELL Technologies - Stemcell.com
New PneumaCult™-ALI Medium for Air-Liquid Interface Culture of Bronchial Epithelial Cells

 

NewswireToday - /newswire/ - Vancouver, British Columbia, Canada, 2012/06/06 - A new culture medium for more physiologically relevant differentiation of human bronchial epithelial cells has been released by STEMCELL Technologies - Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cells cultured with PneumaCult™-ALI at the air-liquid interface (ALI) undergo extensive mucociliary differentiation to form a pseudostratified epithelium that closely resembles the human airway.

“Culturing primary human bronchial epithelial cells at the ALI using current methods often results in unsatisfactory and inconsistent differentiation”, commented Michael Riedel, a Scientist at STEMCELL Technologies. “Importantly, the morphology of cultures grown in PneumaCult™-ALI more closely and more consistently resemble the human airway, compared to other formulations”. Differentiated PneumaCult™-ALI cultures display highly motile cilia, produce and secrete mucus, and develop stable transepithelial electrical resistance.

The development of convenient, yet physiologically relevant in vitro culture systems is critical to research and development on chronic respiratory diseases such as asthma or COPD, and could accelerate the development of inhaled drug formulations. STEMCELL Technologies is proud to support respiratory research with new PneumaCult™-ALI. For more information about PneumaCult™-ALI, please watch our short video or visit our product page.

Contact
Kristy Favell, MSc, Product Manager
STEMCELL Technologies Inc
P: 604-668-0875

About STEMCELL Technologies

STEMCELL Technologies, Inc. (stemcell.com) is a leader in the development and marketing of specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science and enabled by close interactions with global leaders in cell biology and medicine, STEMCELL delivers over 1000 products to research scientists in more than 70 countries worldwide. As “Scientists Helping Scientists,” STEMCELL delivers over 1000 products to more than 70 countries worldwide and provides leadership with services including hands-on training courses, proficiency testing, and contract services. To learn more about how STEMCELL helps to make research work, visit .

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New PneumaCult™-ALI Medium for Air-Liquid Interface Culture of Bronchial Epithelial Cells

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

STEMCELL Technologies |
Publisher Contact: Simon Hilcove - Stemcell.com 
604-675-7898 simon.hilcove[.]stemcell.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)